Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Jacobson-Kram

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Regulatory Toxicology and Pharmacology : RTP|October 11, 2020
A critical review of the acetaminophen preclinical carcinogenicity and tumor promotion data and their implications for its carcinogenic hazard potentialF Jay Murray, Andrew D Monnot, David Jacobson-Kram, et al.
Environmental and Molecular Mutagenesis|August 27, 2010
New and emerging technologies for genetic toxicity testingAnthony M Lynch, Jennifer C Sasaki, Rosalie Elespuru, et al.
Regulatory Toxicology and Pharmacology : RTP|August 1, 2014
Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trialsFiona Sewell, Kathryn Chapman, Paul Baldrick, et al.
Nature Reviews. Drug Discovery|June 2, 2010
Voluntary exploratory data submissions to the US FDA and the EMA: experience and impactFederico M Goodsaid, Shashi Amur, Jiri Aubrecht, et al.
Nature Biotechnology|May 12, 2010
Towards consensus practices to qualify safety biomarkers for use in early drug developmentFrank D Sistare, Frank Dieterle, Sean Troth, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|February 19, 2008
Interlaboratory evaluation of genomic signatures for predicting carcinogenicity in the ratMark R Fielden, Alex Nie, Michael McMillian, et al.
Nature Biotechnology|May 12, 2010
Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing ConsortiumFrank Dieterle, Frank Sistare, Federico Goodsaid, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Regulatory Toxicology and Pharmacology : RTP|October 11, 2020
A critical review of the acetaminophen preclinical carcinogenicity and tumor promotion data and their implications for its carcinogenic hazard potentialF Jay Murray, Andrew D Monnot, David Jacobson-Kram, et al.
Environmental and Molecular Mutagenesis|August 27, 2010
New and emerging technologies for genetic toxicity testingAnthony M Lynch, Jennifer C Sasaki, Rosalie Elespuru, et al.
Regulatory Toxicology and Pharmacology : RTP|August 1, 2014
Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trialsFiona Sewell, Kathryn Chapman, Paul Baldrick, et al.
Nature Reviews. Drug Discovery|June 2, 2010
Voluntary exploratory data submissions to the US FDA and the EMA: experience and impactFederico M Goodsaid, Shashi Amur, Jiri Aubrecht, et al.
Nature Biotechnology|May 12, 2010
Towards consensus practices to qualify safety biomarkers for use in early drug developmentFrank D Sistare, Frank Dieterle, Sean Troth, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|February 19, 2008
Interlaboratory evaluation of genomic signatures for predicting carcinogenicity in the ratMark R Fielden, Alex Nie, Michael McMillian, et al.
Nature Biotechnology|May 12, 2010
Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing ConsortiumFrank Dieterle, Frank Sistare, Federico Goodsaid, et al.
Pageof 4